Does sex alter the relationship between <i>CYP2B6</i> variation, hydroxybupropion concentration and bupropion‐aided smoking cessation in African Americans? A moderated mediation analysis

Chenoweth, Meghan J.; Peng, Annie R.; Zhu, Andy Z.X.; Cox, Lisa Sanderson; Nollen, Nicole L.; Ahluwalia, Jasjit S.; Benowitz, Neal L.; Knight, Jo; Swardfager, Walter; Tyndale, Rachel F.

doi:10.1111/add.15742

Cited by 3 publications

(3 citation statements)

References 44 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies used self-reported race to conduct studies exclusively in participants who identified as African American or Black ( Ho et al, 2009 ; Zhu et al, 2012 ; Zhu et al, 2014b ). Two studies used GWAS-based principal components to identify African ancestry (AFR) populations and conduct a single-group association study ( Chenoweth et al, 2018 ; Chenoweth et al, 2022 ). Two studies reflect a homogeneous group of participants without details on race, ethnic, or ancestry measurement-one study with Han Chinese participants and one study conducted in Korea.…”

Section: Resultsmentioning

confidence: 99%

A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations

Prom-Wormley,

Wells,

Landes

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Abstinence rates among smokers attempting to quit remain low despite the wide availability and accessibility of pharmacological smoking cessation treatments. In addition, the prevalence of cessation attempts and abstinence differs by individual-level social factors such as race and ethnicity. Clinical treatment of nicotine dependence also continues to be challenged by individual-level variability in effectiveness to promote abstinence. The use of tailored smoking cessation strategies that incorporate information on individual-level social and genetic factors hold promise, although additional pharmacogenomic knowledge is still needed. In particular, genetic variants associated with pharmacological responses to smoking cessation treatment have generally been conducted in populations with participants that self-identify as White race or who are determined to be of European genetic ancestry. These results may not adequately capture the variability across all smokers as a result of understudied differences in allele frequencies across genetic ancestry populations. This suggests that much of the current pharmacogenetic study results for smoking cessation may not apply to all populations. Therefore, clinical application of pharmacogenetic results may exacerbate health inequities by racial and ethnic groups. This scoping review examines the extent to which racial, ethnic, and ancestral groups that experience differences in smoking rates and smoking cessation are represented in the existing body of published pharmacogenetic studies of smoking cessation. We will summarize results by race, ethnicity, and ancestry across pharmacological treatments and study designs. We will also explore current opportunities and challenges in conducting pharmacogenomic research on smoking cessation that encourages greater participant diversity, including practical barriers to clinical utilization of pharmacological smoking cessation treatment and clinical implementation of pharmacogenetic knowledge.

show abstract

Section: Resultsmentioning

confidence: 99%

A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations

Prom-Wormley,

Wells,

Landes

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Genetic variants that lead to disease susceptibility or treatment heterogeneity should be identified and differences in variant frequency among ancestry groups determined. Chenoweth et al skillfully employed one approach by employing narrow inclusion criteria (African Americans who smoke ≤ 10 cigarettes/week) and analyzing the effects of common genotypes on bupropion-aided smoking cessation [3] This approach allows for smaller study size to examine if differences in smoking cessation efficacy is due in part to known differences in genetic effects on therapy metabolism.…”

mentioning

confidence: 99%

“…Genetics of smoking can provide information about risk that may increase a individual smoker's motivation and ability to quit, as well as provide genetic information that can be used to increase the effectiveness of pharmacotherapy, as investigrated by Chenoweth et al . [3]. The most important public health significance of understanding the genetic influences of smoking will be in translating that knowledge into improved smoking cessation treatment.…”

mentioning

confidence: 99%

Commentary on Chenoweth et al.: Assessing response to interventions for smoking cessation in diverse populations

Young

Hokanson

2022

Addiction

View full text Add to dashboard Cite

Antidepressants for smoking cessation

Hajizadeh

Howes

Theodoulou

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background The pharmacological profiles and mechanisms of antidepressants are varied. However, there are common reasons why they might help people to stop smoking tobacco: nicotine withdrawal can produce short‐term low mood that antidepressants may relieve; and some antidepressants may have a specific effect on neural pathways or receptors that underlie nicotine addiction. Objectives To assess the evidence for the efficacy, harms, and tolerability of medications with antidepressant properties in assisting long‐term tobacco smoking cessation in people who smoke cigarettes. Search methods We searched the Cochrane Tobacco Addiction Group Specialised Register, most recently on 29 April 2022. Selection criteria We included randomised controlled trials (RCTs) in people who smoked, comparing antidepressant medications with placebo or no pharmacological treatment, an alternative pharmacotherapy, or the same medication used differently. We excluded trials with fewer than six months of follow‐up from efficacy analyses. We included trials with any follow‐up length for our analyses of harms. Data collection and analysis We extracted data and assessed risk of bias using standard Cochrane methods. Our primary outcome measure was smoking cessation after at least six months' follow‐up. We used the most rigorous definition of abstinence available in each trial, and biochemically validated rates if available. Our secondary outcomes were harms and tolerance outcomes, including adverse events (AEs), serious adverse events (SAEs), psychiatric AEs, seizures, overdoses, suicide attempts, death by suicide, all‐cause mortality, and trial dropouts due to treatment. We carried out meta‐analyses where appropriate. Main results We included a total of 124 studies (48,832 participants) in this review, with 10 new studies added to this update version. Most studies recruited adults from the community or from smoking cessation clinics; four studies focused on adolescents (with participants between 12 and 21 years old). We judged 34 studies to be at high risk of bias; however, restricting analyses only to studies at low or unclear risk of bias did not change clinical interpretation of the results. There was high‐certainty evidence that bupropion increased smoking cessation rates when compared to placebo or no pharmacological treatment (RR 1.60, 95% CI 1.49 to 1.72; I 2 = 16%; 50 studies, 18,577 participants). There was moderate‐certainty evidence that a combination of bupropion and varenicline may have resulted in superior quit rates to varenicline alone (RR 1.21, 95% CI 0.95 to 1.55; I 2 = 15%; 3 studies, 1057 participants). However, there was insufficient evidence to establish whether a combination of bupropion and nicotine replacement therapy (NRT) resulted in superior quit rates to NRT a...

show abstract

Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion‐aided smoking cessation in African Americans? A moderated mediation analysis

Cited by 3 publications

References 44 publications

A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations

A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations

Commentary on Chenoweth et al.: Assessing response to interventions for smoking cessation in diverse populations

Antidepressants for smoking cessation

Contact Info

Product

Resources

About